A recent study published in Nature Immunology discovered heightened inflammation in severe COVID-19 due to gut fungi.

Blood sample analysis reinforced this discovery when researchers found IgG antibodies against gut fungi and increased lung neutrophils in severe COVID-19 patients.

Further, mouse models validated the role of gut fungi, particularly Candida albicans, in triggering increased neutrophils in both the blood and lungs.

In COVID-19 patients, the long-term effects were noticeable.

A year after the infection, activated stem cells continued targeting fungi, and antifungal antibodies remained in the bloodstream.

Neutrophils and antibodies were reduced by IL-6 blockers and antifungal medications, especially in tocilizumab-treated individuals, suggesting possible treatment options.

Though guidelines stand, findings suggest tailored treatments using antifungal antibodies, which could also be considered a marker of increased risk of COVID-19.